-
Severe and persistent pancreatic pain is difficult to treat because many painkillers do not work in this organ. In a recent study, a team has discovered the reason: A certain endogenous nerve messenger substance is present in the pancreas’ nerves in very high concentrations.
-
Researchers found that in people with celiac disease, following gluten ingestion, certain inflammatory molecules associated with clinical symptoms occur in the bloodstream. These recently discovered biomarkers are the basis for the blood test.
-
Therapy with the PARP inhibitor olaparib prolonged progression-free survival in severely pretreated patients with metastatic castration-resistant prostate cancer and defective DNA repair mechanisms by approximately 4 months compared to hormone therapy with enzalutamide or abiraterone.
-
Food allergies can be caused by the absence of certain intestinal bacteria. Current study results show that the replacement of these intestinal bacteria could make a decisive contribution to the treatment of allergies.
-
The PD-L1 inhibitor atezolizumab, when added to chemotherapy, prolonged the progression-free survival of untreated patients with metastatic bladder cancer from 6.3 to 8.2 months compared to chemotherapy.
-
Additional treatment with abemaciclib or ribociclib may prolong survival in women with advanced hormone receptor-positive and HER-2-negative breast cancer.
-
Tumors with mismatch repair deficiency (MMRD) or tumors with high tumor mutational burden (TMB) respond better to therapy with checkpoint inhibitors than tumors without these properties.
-
New data for prognostic markers in early breast cancer as well as further analyses of the Phase 3 studies TAILORx and KATHERINE were presented at the ESMO Congress 2019 in Barcelona.
-
Could smartphones be used to measure blood pressure? Canadian and Chinese researchers are suggesting that the smartphone camera could be used to make it easier to check blood pressure.
-
A vast array of study results on melanoma were presented by Piotr Rutkowski, from the Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland, during a highlight session at the ESMO Congress 2019.
-
Sarcomas are relatively rare tumors that can occur on the soft tissue or bone. New study data on their treatment was presented by Javier Martin-Broto, Virgen del Rocio University Hospital, Seville, Spain.
-
Treatment with a combined immunotherapy of nivolumab plus low-dose ipilimumab prolonged overall survival compared to chemotherapy in previously untreated patients with advanced NSCLC regardless of PD-L1 expression of the tumor.
-
First-line therapy with osimertinib significantly prolongs overall survival of patients with non-small-cell lung carcinoma (NSCLC) compared to older tyrosine kinase inhibitors. This was shown by the evaluation of survival data from the FLAURA study
-
Three new studies with the PARP inhibitors niraparib, olaparib and veliparib showed a significant reduction in the risk of progression in first-line therapy of women with ovarian cancer.
-
The results of a 2018 comparative study were as good for inhibitors as those achieved with aggressive chemotherapy. The use of these drugs is currently being tested in the so-called ADRISK study at 13 ENT clinics in Germany.
-
Antibodies against the human papillomavirus (HPV) 16 can be detected up to 40 years before the diagnosis of a head and neck tumor. People with HPV16 antibodies also have a much higher risk of oropharyngeal tumors.
-
Researchers at Carnegie Mellon University, USA, have developed a technique to produce biological tissue from collagens using 3D printing. The new method is an important step on the way to printing a first functioning human heart.
-
A recent research project at the Medical University of Innsbruck, Austria found a new mechanism for certain allergic immune reactions. The team investigated lipocalins and identified FPR 3 as the central player of this allergic reaction.
-
Scientists from the Fraunhofer Society in Germany have developed a method to check the condition of human genetic material, to detect the changes at the chemical and molecular level that come with aging. This may open the door to new drugs and to track health or diseases.
-
A recent study by an international team of researchers opens up new possibilities for research into the pathogenesis of hepatitis B viruses. The basis for this is a newly discovered, unusual HB virus in mice.
